Effects of bortezomib on human neuroblastoma cells in Vitro and in a metastatic xenograft model

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1219-1226

  Valentiner, Ursula ^a   Haane, Christina ^a   Nehmann, Nina ^a   Schumacher, Udo ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bortezomib; Metastases; Neuroblastoma; Proteasome inhibitor; Xenograft model

Indexed keywords

BORTEZOMIB;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALORIMETRY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; MITOSIS; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, SCID; MITOSIS; NEUROBLASTOMA; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 64949154023     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Morgenstern BZ, Krivoshik AP, Rodriguez V and Anderson PM: Wilms' tumor and neuroblastoma. Acta Paediatr Suppl 93: 78- 85,2004.
2. Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T and Spix C: Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett 197: 11-17,2003.
3. De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L, Donfrancesco A, Pession A, Provenzi M, di Cataldo A, Rizzo A, Tonini GP, Dallorso S, Conte M, Gambini C, Garaventa A, Bonetti F, Zanazzo A, D'Angelo P and Bruzzi P: Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high- dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 21: 1592-1601, 2003.
4. Maris JM, Hogarty MD, Bagatell R and Cohn SL: Neuroblastoma. Lancet 369: 2106-2120, 2007.
5. Schumacher U and Adam E: Lectin histochemical HPA-binding pattern of human breast and colon cancers is associated with metastases formation in severe combined immunodeficient mice. Histochem J 29: 677-684, 1997.
6. Schumacher U and Mitchell BS: Use of clinically relevant human-scid-mouse models in metastasis research. Trends Biotechnol 15: 239-241, 1997.
7. Thies A, Mauer S, Fodstad O and Schumacher U: Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice. Br J Cancer 96: 609-616, 2007.
8. Valentiner U, Hall DM, Brooks SA and Schumacher U: HPA binding and metastasis formation of human breast cancer cell lines transplanted into severe combined immunodeficient (scid) mice. Cancer Lett 279: 233-242, 2005.
9. Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5: 417-421, 2004.
10. Richardson PG and Anderson KC: Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol 1: 596-600, 2003.
11. Adams J: The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29(Suppl 1): 3-9, 2003.
12. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999.
13. Bold RJ, Virudachalam S and McConkey DJ: Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100: 11-17,2001.
14. Frankel A, Man S, Elliott P, Adams J and Kerbel RS: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6: 3719-3728, 2000.
15. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome inhibitor PS- 341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076,2001.
16. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM and Perez-Soler R: Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9: 1145-1154, 2003.
17. Olivier S, Robe P and Bours V: Can NF-kappaB be a target for novel and efficient anticancer agents? Biochem Pharmacol 72: 1054-1068, 2006.
18. Pham LV, Tamayo AT, Yoshimura LC, Lo P and Ford RJ: Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171: 88-95, 2003.
19. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J and Callery MP: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82: 110-122, 2001.
20. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P and Van Waes C: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor- kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7: 1419-1428, 2001.
21. Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, Camphausen K, Gius D, Adams J, Sausville EA and Conley BA: Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63: 1400-1412,2005.
22. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G and Ponzoni M: Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 98: 1142-1157, 2006.
23. Hamner JB, Dickson PV, Sims TL, Zhou J, Spence Y, Ng CY and Davidoff AM: Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery 142: 185-191,2007.
24. Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW and Cinatl J Jr: Anticancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 28: 439-446, 2006.
25. Kerr JF, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
26. Hall PA: Assessing apoptosis: a critical survey. Endocr Relat Cancer 6: 3-8, 1999.
27. Sharma R, Adam E and Schumacher U: The action of 5- fluorouracil on human HT29 colon cancer cells grown in SCID mice: mitosis, apoptosis and cell differentiation. Br J Cancer 76: 1011-1016, 1997.
28. Jojovic M and Schumacher U: Quantitative assessment of spontaneous lung metastases of human HT29 colon cancer cells transplanted into SCID mice. Cancer Lett 152: 151-156, 2000.
29. Schneider T, Osl F, Friess T, Stockinger H and Scheuer WV: Quantification of human Alu sequences by real-time PCR - an improved method to measure therapeutic efficacy of anti- metastatic drugs in human xenotransplants. Clin Exp Metastasis 19: 571-582, 2002.
30. Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R and Puisieux A: Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer 7: 50, 2008.
31. Lorch JH, Thomas TO and Schmoll HJ: Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 67: 727-734, 2007.
32. Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA and Anderson KC: Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 111: 1654-1664,2008.
33. Valentiner U, Valentiner FU and Schumacher U: Expression of CD44 is associated with a metastatic pattern of human neuroblastoma cells in a SCID mouse xenograft model. Tumour Biol 29: 152-160,2008.
34. Rajkumar SV, Richardson PG, Hideshima T and Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630-639, 2005.
35. Boccadoro M, Morgan G and Cavenagh J: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 5: 18, 2005.
36. Khan T, Stauffer JK, Williams R, Hixon JA, Salcedo R, Lincoln E, Back TC, Powell D, Lockett S, Arnold AC, Sayers TJ and Wigginton JM: Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors. J Immunol 176: 6302-6312, 2006.